AGAriane Germeyer

Ariane Germeyer

*This is an algorithmically generated author record based on publicly available information.

Ariane Germeyer has a total of 48 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    High multiple pregnancy rates after double embryo transfers in human: a retrospective cohort study

    by Jens Erik Dietrich, Ingrid Cáceres Valcárcel, Edison Capp, Thomas Strowitzki, Ariane Germeyer

    To improve clinical outcomes of human medically assisted reproduction, the transfer of multiple embryos is frequently performed. This leads to high rates of multiple pregnancies. In this study we explored if a cohort of patients can be defined, that benefits from the transfer of two embryos while mitigating the odds of multiple pregnancies by considering female patients’ age, embryo quality and embryo cohort quality. In this retrospective cohort study, clinical pregnancy rate (CPR), live birth rate (LBR) and multiple pregnancy rate (MPR) after fresh single embryo transfers (SETs, n = 245) were compared to those after double embryo transfer (DET, n = 278). Female patient’s age, embryo quality and embryo cohort quality were used to explore clinical outcomes in subgroups. Overall, this study found that compared to SET, DET significantly increased the CPR (33.5 vs 49.6%, adjusted odds ratio (aOR): 2.233, 95% CI: 1.529–3.261, P < 0.001), LBR (24.1 vs 39.2%, aOR: 2.416, 1.605–3.636, P < 0.001) and MPR (0.0 vs 25.4%, P < 0.001). Subgroup analysis based on female age, embryo quality and further stratification based on embryo cohort score revealed that the MPR in all subgroups was high after DET and a subgroup with significantly reduced MPR after DET could not be defined. In conclusion, DETs are associated with high MPRs that cannot be avoided by considering female patients’ age, embryo quality and embryo cohort quality. SET is the most effective way to avoid a multiple pregnancy. Lay summary: This study examined whether it is possible to avoid multiple pregnancies in treatments of assisted reproduction when two embryos are transferred to certain patients. Transferring more than one embryo can increase the chances of pregnancy and live birth but also raises the risk of multiple pregnancies. Multiple pregnancies are linked to health risks for both the mother and the children. Using data from a single clinic, this study explored whether there are specific patients who could benefit from the transfer of two embryos while still having a lower risk of multiple pregnancy. However, the researchers found that DETs consistently lead to high rates of multiple pregnancies, even when factors like the mother’s age, embryo quality and overall embryo cohort quality are considered. The researchers concluded that transferring a single embryo remains the safest approach to prevent multiple pregnancies.


  • Open Access

    Predictors of partnership and sexual satisfaction and dyadic effects in couples affected by endometriosis and infertility

    by Deborah van Eickels, Maren Schick, Ariane Germeyer, Sabine Rösner, Thomas Strowitzki, Tewes Wischmann, Beate Ditzen

    Purpose: Endometriosis and infertility are associated with impaired partnership and sexuality of the patients, but also of their male partners. Also, endometriosis is one of the most common causes of infertility, resulting in a large overlap of both pathologies. The aim of this study was to determine the association of different predictors of partnership and sexual satisfaction and dyadic effects in couples with endometriosis and infertility. Methods: A cross-sectional study was conducted with n = 62 women with endometriosis and n = 46 partners, including a total of n = 44 couples, some of whom were affected by infertility. The questionnaire included items on partnership, sexuality, depression, social support, and desire for a child. Multiple linear regression and the actor-partner-interdependence-model were used for analysis. Results: Significant dyadic effects only occurred in couples with both endometriosis and infertility. Depression showed a significant negative actor effect in men for partnership satisfaction and a negative actor and partner effect in women for sexuality satisfaction (p < .05). For women, social support showed a significant positive actor effect for partnership satisfaction (p < .05), age showed a significant actor and partner effect for sexuality satisfaction (p < .05). Conclusion: The results show a significant association of endometriosis and infertility with partnership and sexuality satisfaction. Infertility could be a decisive factor. However, the large overlapping of both endometriosis und infertility in many couples support the importance of further studies to differentiate between the both effects. Trial registration: German Clinical Trials Register DRKS00014362 on the 29.03.2018.


  • Open Access

    Evaluation of the Gonadotoxicity of Cancer Therapies to Improve Counseling of Patients About Fertility and Fertility Preservation Measures: Protocol for a Retrospective Systematic Data Analysis and a Prospective Cohort Study

    by Michael von Wolff, Ariane Germeyer, Bettina Böttcher, Isotta Martha Magaton, Irene Marcu, Janna Pape, Nicole Sänger, Verena Nordhoff, Marie Roumet, Susanna Weidlinger

    Background: Cytotoxic treatments such as chemo- and radiotherapy and immune therapies are required in cancer diseases. These therapies have the potential to cure patients but may also have an impact on gonadal function and, therefore, on fertility. Consequently, fertility preservation treatments such as freezing of gametes and gonadal tissue might be required. However, as detailed data about the necessity to perform fertility preservation treatment are very limited, this study was designed to fill this data gap. Objective: Primary objective of this study is to analyze the impact of cancer therapies and chemotherapies on the ovarian reserve and sperm quality. Secondary objectives are to analyze the (1) impact of cancer therapies and chemotherapies on other fertility parameters and (2) probability of undergoing fertility preservation treatments in relation to specific cancer diseases and treatment protocols and the probability to use the frozen gametes and gonadal tissue to achieve pregnancies. Methods: First, previously published studies on the gonadotoxicity of chemo- and radiotherapies among patients with cancer will be systematically analyzed. Second, a prospective cohort study set up by approximately 70 centers in Germany, Switzerland, and Austria will collect the following data: ovarian function by analyzing anti-Müllerian hormone (AMH) concentrations and testicular function by analyzing sperm parameters and total testosterone immediately before and around 1 year after gonadotoxic therapies (short-term fertility). A follow-up of these fertility parameters, including history of conceptions, will be performed 5 and 10 years after gonadotoxic therapies (long-term fertility). Additionally, the proportion of patients undergoing fertility-preserving procedures, their satisfaction with these procedures, and the amount of gametes and gonadal tissue and the children achieved by using the frozen material will be analyzed. Third, the data will be merged to create the internet-based data platform FertiTOX. The platform will be structured in accordance with the ICD (International Classification of Diseases) classification of cancer diseases and will be easily be accessible using a specific App. Results: Several funding bodies have funded this study. Ten systematic reviews are in progress and the first one has been accepted for publication. All Swiss and many German and Austrian ethics committees have provided their approval for the prospective cohort study. The study registry has been set up, and a study website has been created. In total, 50 infertility centers have already been prepared for data collection, which started on December 1, 2023. Conclusions: The study can be expected to bridge the data gap regarding the gonadotoxicity of cancer therapies to better counsel patients about their infertility risk and their need to undergo fertility preservation procedures. Initial data are expected to be uploaded on the FertiTOX platform in 2026. Trial Registration: ClinicalTrials.gov NCT05885048; https://clinicaltrials.gov/study/NCT05885048 International Registered Report Identifier (IRRID): DERR1-10.2196/51145


  • Open Access

    Evaluation of the Gonadotoxicity of Cancer Therapies to Improve Counseling of Patients About Fertility and Fertility Preservation Measures: Protocol for a Retrospective Systematic Data Analysis and a Prospective Cohort Study (Preprint)

    by Michael von Wolff, Ariane Germeyer, Bettina Böttcher, Isotta Martha Magaton, Irene Marcu, Janna Pape, Nicole Sänger, Verena Nordhoff, Marie Roumet, Susanna Weidlinger

    BACKGROUND Cytotoxic treatments such as chemo- and radiotherapy and immune therapies are required in cancer diseases. These therapies have the potential to cure patients but may also have an impact on gonadal function and, therefore, on fertility. Consequently, fertility preservation treatments such as freezing of gametes and gonadal tissue might be required. However, as detailed data about the necessity to perform fertility preservation treatment are very limited, this study was designed to fill this data gap. OBJECTIVE Primary objective of this study is to analyze the impact of cancer therapies and chemotherapies on the ovarian reserve and sperm quality. Secondary objectives are to analyze the (1) impact of cancer therapies and chemotherapies on other fertility parameters and (2) probability of undergoing fertility preservation treatments in relation to specific cancer diseases and treatment protocols and the probability to use the frozen gametes and gonadal tissue to achieve pregnancies. METHODS First, previously published studies on the gonadotoxicity of chemo- and radiotherapies among patients with cancer will be systematically analyzed. Second, a prospective cohort study set up by approximately 70 centers in Germany, Switzerland, and Austria will collect the following data: ovarian function by analyzing anti-Müllerian hormone (AMH) concentrations and testicular function by analyzing sperm parameters and total testosterone immediately before and around 1 year after gonadotoxic therapies (short-term fertility). A follow-up of these fertility parameters, including history of conceptions, will be performed 5 and 10 years after gonadotoxic therapies (long-term fertility). Additionally, the proportion of patients undergoing fertility-preserving procedures, their satisfaction with these procedures, and the amount of gametes and gonadal tissue and the children achieved by using the frozen material will be analyzed. Third, the data will be merged to create the internet-based data platform FertiTOX. The platform will be structured in accordance with the ICD (International Classification of Diseases) classification of cancer diseases and will be easily be accessible using a specific App. RESULTS Several funding bodies have funded this study. Ten systematic reviews are in progress and the first one has been accepted for publication. All Swiss and many German and Austrian ethics committees have provided their approval for the prospective cohort study. The study registry has been set up, and a study website has been created. In total, 50 infertility centers have already been prepared for data collection, which started on December 1, 2023. CONCLUSIONS The study can be expected to bridge the data gap regarding the gonadotoxicity of cancer therapies to better counsel patients about their infertility risk and their need to undergo fertility preservation procedures. Initial data are expected to be uploaded on the FertiTOX platform in 2026. CLINICALTRIAL ClinicalTrials.gov NCT05885048; https://clinicaltrials.gov/study/NCT05885048 INTERNATIONAL REGISTERED REPORT DERR1-10.2196/51145

  • Hormonelle und soziale Einflüsse auf Endometriose-Schmerzen

    by K Van Stein, M Eckstein, M Schick, T Wischmann, B Ditzen, A Germeyer, A Marshall

    Zielsetzung Soziale Einflussfaktoren wie Unterstützung, aber auch Stress, können das Schmerzerleben entscheidend beeinflussen, wie Forschung z.B. bei chronischen Rückenschmerzen zeigen konnte. Gleichzeitig unterscheidet sich die neurale Schmerzverarbeitung chronischer Schmerzpatient*innen von der von Gesunden. Für Endometriose-Betroffene gibt es in diesem Bereich noch wenig systematische Untersuchungen. In zwei Studien soll daher untersucht werden: a) wie sich Stress und soziale Unterstützung auf chronische Unterbauchschmerzen im Alltag auswirken. b) wie sich die neurale Verarbeitung von akuten Schmerzreizen bei Endometriose-Betroffenen von der einer gesunden Kontrollgruppe unterscheidet. Materialien In beiden Studien werden Speichelproben für die Analyse von Cortisol-, Oxytocin-, Progesteron- und Estradiolwerten erhoben. Außerdem werden Fragebögen zu psychischen Symptomen, Trauma, Schmerz, Stress, Partnerschaft und sexueller Gesundheit beantwortet. Methoden a) Alltagserhebung: Die Proband*innen (N=60) und ggf. deren Partner*innen füllen über eine Woche täglich jeweils sieben kurze Fragebögen zum aktuellen Befinden auf Smartphones aus. Dazu gehören das Schmerzlevel und die soziale Situation (Unterstützung, Konflikte). b) fMRT-Studie: Die Proband*innen (N=60) erhalten leichte elektrische Schmerzreize, zunächst in einer No-Stress-Bedingung und später in einer sozialen Stresssituation. Die neurale Schmerzverarbeitung wird analysiert und verglichen mit der einer gesunden Kontrollgruppe. Ergebnisse Die Datenerhebung läuft bis Januar 2023. Zusammenfassung In dieser aktuell noch laufenden Doppelstudie wird das Schmerzerleben Endometriose-Betroffener in Abhängigkeit von sozialen Einflussfaktoren untersucht sowie die neurale Schmerzverarbeitung Endometriose-Betroffener unter Ruhe- und Stressbedingungen mit der einer gesunden Kontrollgruppe verglichen. Die hieraus gewonnenen Erkenntnisse sollen als Grundlage dienen, die zentralnervöse Schmerzverarbeitung sowie soziale und endokrine Mechanismen in der Schmerzwahrnehmung besser zu verstehen und langfristig Therapiemöglichkeiten zu verbessern. Article published online: 11 October 2022 © 2022. Thieme. All rights reserved. Georg Thieme Verlag Rüdigerstraße 14, 70469 Stuttgart, Germany

  • Embryo cohort quality impacts on the outcome of Medically Assisted Reproduction (MAR)

    by I Valcárcel Cáceres, Je Dietrich, E Capp, T Strowitzki, A Germeyer

    Zielsetzung While the number of untransferred embryos is positively correlated with the implantation potential, this study aimed to clarify to what extend the quality of the cultivated embryo cohort score (ECS) influences the pregnancy success rates. Materialien A retrospective analysis of pregnancy outcome in 523 fresh ART cycles from 10/2016 to 06/2020 (n = 1913 embryos) was performed. Embryo morphology was scored on the day of transfer (day 4 or day 5). The ECS was calculated as the mean score of all cultured embryos of the same cycle. Poisson linear regression was used to assess the relationship between scores and outcome. Ergebnisse The embryo transfer from high quality cohorts (HECS) (≥ 1.6) resulted in significantly higher clinical pregnancy rates: 2,1-fold after Single Embryo Transfer (SET) (p= 0.006) and 3.7-fold after Double Embryo Transfer (DET) (p= 0.005) compared to low quality cohorts (LECS) (≤ 0.5). For further analyses subgroups based on female age were created. The impact of a HECS was statistically significant only for the patients ≥35 years: 2.37-fold after SET (p= 0.031) and 8.89-fold after DET (p= 0.026). In addition, only a DET of HECS lead to more pregnancies than a SET with HECS in women below 35, but not in older women. Zusammenfassung These data suggest that embryo cohort scores affect the clinical outcome and may be considered when determining the number of embryos for transfer. A limiting factor was the small total number of fertilized oocytes used for in-vitro culturing due to legal regulations in Germany. Article published online: 11 October 2022 © 2022. Thieme. All rights reserved. Georg Thieme Verlag Rüdigerstraße 14, 70469 Stuttgart, Germany

  • Open Access

    O-033 Ovarian tissue transplantations in 196 women by FertiPROTEKT– live birth rate of 26.5% per woman is associated with female age and first versus repeated transplantation

    by L Lotz, J Bender-Liebenthron, R Dittrich, L Häberle, M W Beckmann, A Germeyer, M Korell, N Sänger, M Von Wolff

    What is the live birth rate of ovarian tissue transplantation and which factors are associated with the success rate? Live birth rate per transplanted woman is 26.5% and the success rate is associated with female age and first versus repeated transplantation. Live birth rates after tissue transplantations have been reported to be between around 24% and 41% per patient. Success rates seem to be negatively associated with increasing female age at the time of tissue cryopreservation and with pelvic radiation. Success rates are apparently not reduced after overnight transportation of tissue before freezing. Registry analysis of 244 transplantations in 196 women, performed by 26 centers of the FertiPROTEKT network from 2007 to 2019 with a follow up till 12/2020. Orthotopic transplantation was performed in 196 women, 191 with previous malignant and 5 with previous non-malignant diseases. Size of transplanting centers varied between 1 and 100 transplantations per center (average: 9.5 ± 19.6 transplantations). Factors possibly associated with success rate such as female age, first and repeated transplantation, experience of the transplanting center and overnight transportation of the tissue before freezing were analysed. Average age of all transplanted 196 women was 31.3 years (SD, standard deviation, 5.2) at the time of cryopreservation (range 17-44y) and 35.9 years (SD 4.8, range 23-47) at the time of first transplantation. Overall pregnancy rate was 30.6% (95% CI, 24.2-37.6%) per first transplantation and 32.7% (95% CI, 26.1-39.7) per patient. Overall live birth rate per first transplantation was 25.0% (95% CI, 19.1-31.7%) and per patient 26.5% (95% CI, 20.5-33.3%). Pregnancy and live birth rates were calculated and graphically expressed as a continuous function of age to allow estimation of success rates per age group. Success rate decreased with increasing age at the time of tissue freezing. Pregnancy rate after first transplantation was 34.5% (95% CI, 26.7-42.9%) in women st transplantation (30.6% (95% CI, 24.2-37.6%)) compared to 2nd and more transplantations (11.8% (95% CI, 3.3-27.5%)). Pregnancy rates after 1st transplantation was higher in centers with ≥10 transplantations (35.1%) compared to centers with <10 transplantation (25.4%) (p = 0.12). Corresponding live birth rates were 27.0% and 18.6%. Success rates was not different in women with and without overnight transportation of tissue before cryopreservation. The data were drawn from a registry analysis. Data such as ovarian reserve and premature ovarian insufficiency were not available for all women. Data might be influenced by different follow up policies of the centers. The study reveals the high potential of ovarian tissue freezing and transplantation but only if freezing is performed in younger women. The study suggests to better focus on the first and not on repeated transplantations. It also opens the discussion if transplantation should rather be performed by experienced centres. Non

  • Maternal erythrocyte fatty acid composition as a predictive marker for pregnancy health

    by Shabnam Fayezi, Amir Mehdizadeh, Ariane Germeyer, Thomas Strowitzki, Parisa Fayyazpour, Zahra Nowrouzi, Reza Zarezadeh

    Pregnancy is accompanied by a surge in demand for fatty acids (FAs) in order to support maternal health, as well as fetal growth and development. Of particular demand is essential for long‐chain polyunsaturated FAs. FAs are primarily obtained from dietary sources and are distributed in the body. In comparison with the use of self‐reporting approaches, measuring the FA levels within different blood compartments can present a more accurate image of nutritional, and thus tissue, FA composition. Hence, the FA profile of plasma or serum is commonly used for physiological analyses. Nevertheless, plasma and serum FAs are not yet incorporated into cell membranes, and consequently may not be a suitable reflection of the FA status of body tissues. The evaluation of erythrocyte FA levels offers a superior possibility for the following reasons: the biological fluctuation of erythrocyte FA composition is low, phospholipids account for almost all the lipid content of erythrocytes, and the FA profiles of erythrocytes represent those of tissues. Here, we elaborate on whether the status of maternal erythrocyte FAs can serve as a prognostic biomarker for reproductive health and fetomaternal complications, including embryonic and fetoplacental development, gestational length, and preeclampsia. In addition, factors with the potential of altering the maternal erythrocyte FAs such as maternal diet, lifestyle habits, genetics, and body composition are discussed.


  • Expression of semaphorin class 3 is higher in the proliferative phase on the human endometrium

    by Gustavo Dias Ferreira, Edison Capp, Julia Jauckus, Thomas Strowitzki, Ariane Germeyer

    The semaphorins are related to angiogenesis and cell proliferation depending on the tissue. The purpose of this study was to assess gene expression of class 3 semaphorin (SEMA3A-F) and protein expression of semaphorin 3A (SEMA3A) within human endometrium throughout the menstrual cycle.